Stent type used does not impact complication rate or placement time but can decrease treatment cost for benign and malignant esophageal lesions

Table 3 Patient characteristics based on stent type placed

	SEMS (n = 30)	SEPS (n = 13)	P value
Mean age (yr ± SD)	59.6 ± 14.87	61.7 ± 9.95	0.645
% male	83.3%	76.9%	0.681
Race/ethnicity, n (%)	AA: 9 (30%)	AA: 6 (46%)	0.704
	nHw: 18 (60%)	nHw: 7 (54%)
	Other: 3 (10%)	Other: 0
Malignant esophageal lesion, n (%)	25 (83.3%)	10 (76.9%)	0.681
Esophageal lesion location, n (%)	Upper third: 0	Upper third: 1 (7.7%)	0.15
	Middle third: 9 (30%)	Middle third: 6 (46.2%)
	Lower third: 21 (70%)	Lower third: 6 (46.2%)
Comorbid diseases, n (%)	HTN: 16 (53.3%)	HTN: 6 (46.2%)	0.747
	CAD: 7 (23.3%)	CAD: 2 (15.4%)	0.699
	COPD: 5 (16.7%)	COPD: 1 (7.7%)	0.649
	DM: 11 (36.7%)	DM: 3 (23.1%)	0.491

SEMS: Self-expanding esophageal metal stents; SEPS: Self-expanding esophageal plastic stents; nHw: Non-Hispanic White; AA: African American; HTN: Hypertension; CAD: Coronary artery disease; COPD: Chronic obstructive pulmonary disease; DM: Diabetes mellitus.